Cobicistat
- Generic Name
- Cobicistat
- Brand Names
- Evotaz, Genvoya, Prezcobix, Rezolsta, Stribild, Tybost
- Drug Type
- Small Molecule
- Chemical Formula
- C40H53N7O5S2
- CAS Number
- 1004316-88-4
- Unique Ingredient Identifier
- LW2E03M5PG
- Background
Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that ar...
- Indication
Cobicistat is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. It is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir due...
- Associated Conditions
- Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
- Conditions
- Interventions
- Drug: Bictegravir (BIC)Drug: Doravirine (DOR)Drug: Tenofovir alafenamide (TAF)Drug: Dolutegravir (DTG)Drug: Cabotegravir (CAB)Drug: Atazanavir/ritonavir (ATV/r)Drug: Lopinavir/ritonavir (LPV/r)Drug: Second-Line TB TreatmentDrug: CobicistatDrug: First-Line TB TreatmentDrug: Darunavir/ritonavir (DRV/r)Drug: Ritonavir
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2024-08-21
- Target Recruit Count
- 325
- Registration Number
- NCT04518228
- Locations
- 🇺🇸
Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States
🇺🇸Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States
🇿🇦Wits RHI Shandukani Research, Johannesburg, Gauteng, South Africa
A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time
- Conditions
- Interventions
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 34
- Registration Number
- NCT04263350
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate Agents
- Conditions
- Interventions
- First Posted Date
- 2020-01-22
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Target Recruit Count
- 16
- Registration Number
- NCT04236453
- Locations
- 🇳🇱
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 413
- Registration Number
- NCT04065399
- Locations
- 🇫🇷
Hospital Saint-Louis - APHP, Paris, France
🇫🇷Centre Hospitalier Universitaire (CHU) de Bordeaux, Pessac, France
🇩🇪University Hospital Of Ulm, Universitatsklinikum Ulm, Ulm, Baden-Württemberg, Germany
Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers
- Conditions
- Interventions
- First Posted Date
- 2019-03-06
- Last Posted Date
- 2023-12-01
- Target Recruit Count
- 12
- Registration Number
- NCT03864406
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Pharmacokinetic Boosting of Osimertinib
- First Posted Date
- 2019-02-28
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Academisch Ziekenhuis Maastricht
- Target Recruit Count
- 11
- Registration Number
- NCT03858491
- Locations
- 🇳🇱
Maastricht University Medical Centre, Maastricht, Limburg, Netherlands
🇳🇱Antoni van Leeuwenhoek hospital, Amsterdam, Noord-Holland, Netherlands
Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults
- Conditions
- Interventions
- First Posted Date
- 2017-02-08
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 33
- Registration Number
- NCT03045861
- Locations
- 🇨🇦
GSK Investigational Site, Montreal, Quebec, Canada
First-in-Human Study of an Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor
- First Posted Date
- 2016-01-22
- Last Posted Date
- 2019-01-02
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT02661373
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 126
- Registration Number
- NCT02578550
A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat
- Conditions
- Interventions
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2020-12-07
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT02565888
- Locations
- 🇳🇱
CRCN, Radboud University Medical Center, Nijmegen, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.